Collaborative treatment of primary nephrotic syndrome in children with traditional Chinese and Western medicine

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500101933

Enrollment

Unknown

Registered

2025-05-06

Start date

2025-05-10

Completion date

Unknown

Last updated

2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary nephrotic syndrome

Interventions

Control group (Western Medicine treatment plan):Single intravenous injection of rituximab

Integrated traditional Chinese and Western medicine treatment group:Single intravenous injection of rituximab, and oral administration of the Schisandra chinensis Blood-Activating Formula for combined

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Children with hormone-dependent minimal change nephrotic syndrome, aged 2 to 18 years old, regardless of gender.

Exclusion criteria

Exclusion criteria: Those with concurrent infections, diseases of other organ systems, and abnormal renal function

Design outcomes

Primary

Measure	Time frame
The frequency of disease recurrence;Urinary protein excretion situation;	—

Secondary

Measure	Time frame
Immune function;Coagulation function;Intestinal mucosal permeability;Intestinal flora;Fecal metabolomics;Urine proteomics;	—

Countries

China

Contacts

Public ContactYulin Kang

Shanghai Children’s Hospital

kangyl@shchildren.com.cn+86 182 2199 2381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026